HOVON110/ReBeL Study: results of the phase i part of a randomized phase I/II study of lenalidomide, rituximab with or without bendamustine in patients with relapsed/refractory follicular lymphoma
Authors
Stevens, WBCBakunina, K
Cuijpers, M
Chamuleau, M
Beeker, A
Fijnheer, R
Hebart, H
Visser, HPJ
Doorduijn, JK
Linton, Kim M
Dreyling, M
de Jong, D
Kersten, MJ
Affiliation
Department of Hematology, Radboud University Medical Center, Nijmegen, The NetherlandsIssue Date
2020
Metadata
Show full item recordAbstract
Supplemental Digital Content is available in the text.Citation
Stevens WBC, Bakunina K, Cuijpers M, Chamuleau M, Beeker A, Fijnheer R, et al. HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma. Hemasphere. 2020;4:e325.Journal
HemasphereDOI
10.1097/HS9.0000000000000325PubMed ID
32072141Additional Links
https://dx.doi.org/10.1097/HS9.0000000000000325Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1097/HS9.0000000000000325
Scopus Count
Collections
Related articles
- A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
- Authors: Witzig TE, Nowakowski GS, Habermann TM, Goy A, Hernandez-Ilizaliturri FJ, Chiappella A, Vitolo U, Fowler N, Czuczman MS
- Issue date: 2015 Aug
- Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study.
- Authors: Sakai R, Ohmachi K, Sano F, Watanabe R, Takahashi H, Takasaki H, Tanaka M, Hattori Y, Kimura H, Takimoto M, Tachibana T, Tanaka E, Ishii Y, Ishiyama Y, Hagihara M, Miyazaki K, Yamamoto K, Tomita N, Ando K
- Issue date: 2019 Sep
- Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
- Authors: Smith SM, Pitcher BN, Jung SH, Bartlett NL, Wagner-Johnston N, Park SI, Richards KL, Cashen AF, Jaslowski A, Smith SE, Cheson BD, Hsi E, Leonard JP
- Issue date: 2017 Apr
- Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.
- Authors: Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L
- Issue date: 2013 Sep
- Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
- Authors: Morschhauser F, Le Gouill S, Feugier P, Bailly S, Nicolas-Virelizier E, Bijou F, Salles GA, Tilly H, Fruchart C, Van Eygen K, Snauwaert S, Bonnet C, Haioun C, Thieblemont C, Bouabdallah R, Wu KL, Canioni D, Meignin V, Cartron G, Houot R
- Issue date: 2019 Aug